Tetracore(R) Inc. Announces European Approval of the T-COR 8(TM) Portable Real-time PCR Thermocycler

Food and Healthcare Press Releases Monday September 18, 2017 13:42
ROCKVILLE, Maryland--18 Sep--PRNewswire/InfoQuest
  • The next generation molecular diagnostics platform introduces novel connectivity solution designed to bring testing closer to the patient
Tetracore today announced that the T-COR 8 portable real-time PCR thermocycler has achieved CE-IVD status under the European Directive on In Vitro Diagnostic Medical Devices.

The T-COR 8, and proprietary software delivers healthcare providers with a simple, flexible, and accessible molecular diagnostics platform. This unique, and easy to use point-of-care (POC) diagnostic system enables real-time molecular testing in hospitals, clinics, physician offices, and field applications.

Healthcare providers rely on molecular testing to produce accurate identification of infectious agents to aid in selecting targeted therapies quickly. Advances in access to molecular testing support global clinical efforts to improve antibiotic stewardship. Most importantly, near patient diagnostics permits appropriate treatment to begin immediately. Designed for the point of care, the T-COR 8 brings molecular infectious disease testing closer to the patient.

"We are focused on delivering testing to where it is most needed, regardless of the setting," explains Dr. Bill Nelson MD, CEO of Tetracore. "The T-COR 8 empowers more healthcare providers to perform critical tests where it is needed most." Tetracore is developing several diagnostic tests for the system targeting respiratory viruses, hospital acquired infections, and gastrointestinal infectious disease panels. Along with the proprietary content under development, the T-COR 8 is capable of performing molecular tests in an "open" mode, allowing researchers and developers to create new tests on the next generation instrument using the built-in custom protocol creator.

The T-COR 8 Features Include:
  • "Cloud" ready and networkable (WiFi/ethernet) for remote access and data download
  • 8 independently programmable wells
  • Random access instrument, allowing multiple protocols simultaneously
  • 10.4" (26.4cm) touch screen w/virtual keyboard
  • Can be plugged in or run on the built-in battery (up to 4 hours of continuous testing)
  • Integrated barcode scanner
  • Download report via network or USB thumb drive
About Tetracore, Inc.

Tetracore is a biotechnology company specializing in the development and manufacture of diagnostic devices and assays for the detection of infectious diseases. Located in the Biotechnology Corridor in Rockville, Maryland. Tetracore was founded in 1998 by former United Nations Special Commission biological weapons inspectors and scientists of the Naval Medical Research Institute in Bethesda, Maryland.   For more information visit www.tetracore.com   or contact us at jkelly@tetracore.com .

Logo - https://mma.prnewswire.com/media/371337/Tetracore_Logo.jpg

Latest Press Release

ESMO Publishes New Position Paper on Supportive and Palliative Care

ESMO, the leading professional organisation for medical oncology, published a position paper on supportive and palliative care [ https://doi.org/10.1093/annonc/mdx757 ], calling attention to the evolving and growing gap between the needs of cancer...

Koch Disruptive Technologies to Lead $150 Million Investment of INSIGHTEC

The medical device company is transforming neurological treatments through its non-invasive focused ultrasound applications Koch Disruptive Technologies, a subsidiary of Koch Industries focused on finding and funding innovative and emerging companies,...

MediaTek Sensio: New Biosensor Solution Brings Health Monitoring to Smartphones

MediaTek Inc. today unveiled MediaTek Sensio(TM), the first 6-in-1 smartphone biosensor module. MediaTek Sensio is a powerful advanced health monitoring solution which makes it easy to track heart rate information, blood pressure trends, peripheral...

Merck Signs Distribution Agreement with Avanti(R) Polar Lipids

Merck , a leading science and technology company, today announced that it has entered into an agreement with Avanti(R) Polar Lipids to be the exclusive multinational distributor of the USA-based company's research lipids portfolio outside of the United...

Xultophy(R) Significantly Reduces Blood Sugar Levels, Body Weight and Risk of Hypoglycaemia for People With Type 2 Diabetes in Real-World Setting

Newly published data from real-world European clinical practice has shown that Xultophy(R) (insulin degludec/liraglutide) significantly reduced blood sugar levels in people with type 2 diabetes after six months.[1] The study looked at people with type 2...

Related Topics